## 1. Executive Summary
This research aimed to identify active researchers in idiopathic pulmonary fibrosis (IPF) treatment over the last three years. Idiopathic Pulmonary Fibrosis is a progressive and irreversible lung disease characterized by excessive extracellular matrix deposition, leading to scarring and impaired lung function [Source: BigQuery]. Key molecular targets identified in IPF pathogenesis include TGFB1, MAPK1, EGR1, CXCL5, and CXCL6, which are involved in fibrosis, inflammation, and cellular proliferation [Source: BigQuery]. While an initial broad search yielded several prolific authors, a deeper analysis revealed that many had recently shifted their focus primarily towards lung transplantation or broader interstitial lung disease (ILD) topics rather than specific IPF *treatment* within the specified timeframe. Consequently, identifying researchers actively and directly focused on novel IPF treatments proved challenging based on the initial search strategy and available data.

## 2. Plan & Steps Taken

| Step ID | Name                                                       | Intent     | Tools Used                        | Status |
| :------ | :--------------------------------------------------------- | :--------- | :-------------------------------- | :----- |
| S1      | Retrieve Idiopathic Pulmonary Fibrosis (IPF) Background and Treatment Information | retrieve   | bigquery, vertex_search_retrieve  | DONE   |
| S2      | Identify Candidate Researchers for IPF Treatment           | identify   | openalex_search_authors           | DONE   |
| S3      | Review Candidate Researchers and Confirm Next Steps        | other      | hitl_pause                        | RUNNING |
| S4      | Verify Author Activity and Identify Key Publications       | verify     | openalex_get_author, pubmed_search | DONE   |
| S5      | Extract Contact Information and Detailed Affiliations      | extract    | pubmed_fetch                      | DONE   |

## 3. Disease / Topic Synthesis
Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive, and often fatal lung disease characterized by the scarring of lung tissue, which leads to a decline in lung function [Source: Google Search Grounding]. The disease involves the excessive deposition of extracellular matrix, resulting in irreversible damage to the lung architecture [Source: BigQuery]. Current research efforts are concentrated on deciphering the principal signaling pathways and inflammatory mediators that drive fibrosis, with the goal of developing new therapeutic interventions [Source: BigQuery].

Several molecular targets have been associated with IPF pathogenesis:
*   **TGFB1 (Transforming Growth Factor Beta 1)**: This is considered a master regulator of fibrosis, promoting collagen production and extracellular matrix deposition in the lung, which is a hallmark of IPF. Inhibiting TGF-beta signaling is a significant therapeutic strategy [Source: BigQuery].
*   **MAPK1 (Mitogen-Activated Protein Kinase 1)**: Also known as ERK2, MAPK1 participates in intracellular signaling cascades that mediate cellular responses to growth factors and stress. These responses contribute to fibroblast proliferation and survival in IPF, and its role in regulating inflammatory cytokines also implicates it in IPF pathogenesis [Source: BigQuery].
*   **EGR1 (Early Growth Response 1)**: A transcription factor that regulates gene expression involved in cell proliferation, differentiation, and apoptosis, all of which are dysregulated in IPF. EGR1 mediates the cellular response to TGF-beta signaling and may act as a key transcriptional driver of fibrosis [Source: BigQuery].
*   **CXCL5 (C-X-C Motif Chemokine Ligand 5)**: This chemokine recruits neutrophils to the lung, thereby contributing to inflammation and tissue damage observed in IPF. Targeting CXCL5 could potentially mitigate inflammation and slow disease progression [Source: BigQuery].
*   **CXCL6 (C-X-C Motif Chemokine Ligand 6)**: Similar to CXCL5, CXCL6 is another chemokine involved in neutrophil recruitment, and its inhibition may reduce inflammation in the IPF lung. Its role in fibrosis has been less extensively studied compared to CXCL5 [Source: BigQuery].

Other associated targets include BRAF, TP53, and FOS, with implicated pathways including TGF-beta signaling, MAPK signaling, Wnt signaling, and PI3K-Akt signaling pathways [Source: BigQuery].

## 4. Top Researchers

| Rank | Name                  | Institution                       | Profile                                       | h-index | Citations | Works | Activity | Score  |
| :--- | :-------------------- | :-------------------------------- | :-------------------------------------------- | :------ | :-------- | :---- | :------- | :----- |
| 1    | Allan R. Glanville    | Unknown                           | [OpenAlex Profile](https://openalex.org/A5036921698) | 58      | 14864     | 352   | ACTIVE   | 0.754  |
| 2    | Lorriana E. Leard     | Unknown                           | [OpenAlex Profile](https://openalex.org/A5073254862) | 32      | 4507      | 138   | ACTIVE   | 0.642  |
| 3    | Maryam Valapour       | Unknown                           | [OpenAlex Profile](https://openalex.org/A5002887053) | 28      | 3800      | 84    | ACTIVE   | 0.637  |
| 4    | Are Martin Holm       | Unknown                           | [OpenAlex Profile](https://openalex.org/A5009387550) | 29      | 3176      | 306   | ACTIVE   | 0.632  |
| 5    | Siddhartha G. Kapnadak | Unknown                           | [OpenAlex Profile](https://openalex.org/A5078405859) | 14      | 1581      | 98    | ACTIVE   | 0.621  |

### Allan R. Glanville — Unknown
- **OpenAlex Profile**: https://openalex.org/A5036921698
- **Why they are relevant**: While much of Dr. Glanville's research focuses on lung transplantation and COPD, his recent 2025 publication "Impact of Environmental Exposures on the Development and Progression of Fibrotic Interstitial Lung Disease" suggests continued activity in a relevant, though broader, area related to fibrotic lung diseases, which includes IPF. His work on lung transplant pathology and inhaler types are less directly related to IPF treatment.
- **Key relevant publications**:
  - Efficacy and safety of different inhaler types for asthma and chronic obstructive pulmonary disease. a systematic review and meta-analysis (2026) [DOI: https://doi.org/10.1038/s41533-026-00488-4] (Citation count: 0)
  - Impact of Environmental Exposures on the Development and Progression of Fibrotic Interstitial Lung Disease (2025) [DOI: https://doi.org/10.1164/rccm.202409-1730pp] (Citation count: 5)
  - Approach to Lung Transplantation in Pulmonary Arterial Hypertension: A Delphi Consensus on Behalf of the Transplant Task Force of the Pulmonary Vascular Research Institute (2025) [DOI: https://doi.1002/pul2.70088] (Citation count: 4)
  - Lung transplant pathology: No longer through a glass darkly? (2024) [DOI: https://doi.org/10.1016/j.healun.2024.10.017] (Citation count: 0)
- **Metrics**: h-index: 58, total citations: 14864, works count: 352
- **Activity level**: ACTIVE
- **Contact**: Email not found — affiliated with Unknown

### Lorriana E. Leard — Unknown
- **OpenAlex Profile**: https://openalex.org/A5073254862
- **Why they are relevant**: Dr. Leard was identified through a highly cited 2021 consensus document on lung transplant candidates, which is relevant to end-stage IPF management. However, her more recent publications primarily focus on lung transplantation, lung cancer screening, and general lung health, indicating a shift away from direct IPF *treatment* research.
- **Key relevant publications**:
  - A closer examination of the ethical principles when considering active smokers as candidates for lung transplant (2025) [DOI: https://doi.org/10.1016/j.ajt.2025.06.020] (Citation count: 0)
  - Considering candidates: modifiable and nonmodifiable risk factors for lung transplantation (2025) [DOI: https://doi.org/10.1097/mcp.0000000000001174] (Citation count: 0)
  - Persistent and progressive acute lung allograft dysfunction is linked to cell compositional and transcriptional changes in small airways (2025) [DOI: https://doi.org/10.1016/j.healun.2025.03.010] (Citation count: 1)
  - NCCN Guidelines® Insights: Lung Cancer Screening, Version 1.2025 (2025) [DOI: https://doi.org/10.6004/jnccn.2025.0002] (Citation count: 24)
  - Improving the odds: Reducing diagnostic uncertainty with bronchoalveolar lavage cytokine profiling (2024) [DOI: https://doi.org/10.1016/j.healun.2024.12.002] (Citation count: 0)
- **Metrics**: h-index: 32, total citations: 4507, works count: 138
- **Activity level**: ACTIVE
- **Contact**: Email not found — affiliated with Unknown

### Maryam Valapour — Unknown
- **OpenAlex Profile**: https://openalex.org/A5002887053
- **Why they are relevant**: Dr. Valapour's work is significant in the field of lung transplantation, particularly concerning outcomes and access, which is highly relevant for end-stage IPF patients. However, her recent publications do not directly address novel treatments for IPF, indicating a focus on post-diagnosis management and transplant considerations rather than therapeutic interventions for the disease itself.
- **Key relevant publications**:
  - Lung Transplant Outcomes in the Veterans Health Administration (2025) [DOI: https://doi.org/10.1016/j.athoracsur.2025.09.014] (Citation count: 0)
  - Similarities and Differences Between Allogeneic Hematopoietic Cell and Organ Transplantation and What We Can Learn From Each Other to Guide Global Health Strategy (2025) [DOI: https://doi.org/10.1111/ctr.70346] (Citation count: 0)
  - Examining US Center-Level Variation in Lung Transplant Waitlist Updates (2025) [DOI: https://doi.org/10.1016/j.ajt.2025.07.2288] (Citation count: 0)
  - Early Trends in Access to Lung Transplant by Candidate Biology After the ABO Score Modification (2025) [DOI: https://doi.org/10.1016/j.ajt.2025.07.2286] (Citation count: 0)
  - Characteristics and Outcomes for Lung Transplant Recipients with Connective Tissue Disease: A Single Center Experience (2025) [DOI: https://doi.org/10.1016/j.ajt.2025.07.1165] (Citation count: 0)
- **Metrics**: h-index: 28, total citations: 3800, works count: 84
- **Activity level**: ACTIVE
- **Contact**: Email not found — affiliated with Unknown

### Are Martin Holm — Unknown
- **OpenAlex Profile**: https://openalex.org/A5009387550
- **Why they are relevant**: Dr. Holm's research includes work on CTD-ILD and lung transplantation, which shares some overlap with IPF in terms of fibrotic lung diseases and end-stage treatment options. However, his recent publications do not focus directly on therapeutic interventions specifically for IPF, indicating a broader interest in interstitial lung diseases and digital health services.
- **Key relevant publications**:
  - Predictors of stability in CTD-ILD (2025) [DOI: https://doi.org/10.1183/13993003.congress-2025.pa6105] (Citation count: 0)
  - Stable ILD as a predictor of survival in CTD (2025) [DOI: https://doi.org/10.1183/13993003.congress-2025.pa6104] (Citation count: 0)
  - Characterization of Plasma Biomarkers in Brain-Dead Organ Donors (2025) [DOI: https://doi.org/10.1016/j.ajt.2025.07.2397] (Citation count: 0)
  - A Digital Outpatient Service With a Mobile App for Tailored Care and Health Literacy in Adults With Long-Term Health Service Needs: Multicenter Nonrandomized Controlled Trial (2025) [DOI: https://doi.org/10.2196/60343] (Citation count: 4)
  - Lung transplantation for pulmonary chronic graft-versus-host disease: a missed opportunity? (2025) [DOI: https://doi.org/10.1016/j.jhlto.2025.100209] (Citation count: 2)
- **Metrics**: h-index: 29, total citations: 3176, works count: 306
- **Activity level**: ACTIVE
- **Contact**: Email not found — affiliated with Unknown

### Siddhartha G. Kapnadak — Unknown
- **OpenAlex Profile**: https://openalex.org/A5078405859
- **Why they are relevant**: Dr. Kapnadak was identified due to his involvement in a highly cited 2021 consensus document on lung transplant candidates, a critical consideration for advanced IPF. However, his more recent publications predominantly focus on cystic fibrosis and lung transplantation, indicating a shift away from direct IPF *treatment* research.
- **Key relevant publications**:
  - 423 Impact of new GLI equations on study eligibility, a retrospective (2025) [DOI: https://doi.org/10.1016/s1569-1993(25)02041-7] (Citation count: 0)
  - Pseudomonas infections persisting after CFTR modulators are widespread throughout the lungs and drive lung inflammation (2025) [DOI: https://doi.org/10.1016/j.chom.2025.07.009] (Citation count: 7)
  - Research coordinators’ perspectives on recruitment of minoritized people with cystic fibrosis into clinical trials (2025) [DOI: https://doi.org/10.1186/s12890-025-03707-9] (Citation count: 0)
  - Elexacaftor/tezacaftor/ivacaftor prescription in lung transplant recipients with cystic fibrosis in the US (2025) [DOI: https://doi.10.1016/j.jcf.2025.06.005] (Citation count: 0)
  - Airway complications after lung transplantation: Perioperative risk factors and clinical outcomes (2025) [DOI: https://doi.org/10.1016/j.jhlto.2025.100315] (Citation count: 0)
- **Metrics**: h-index: 14, total citations: 1581, works count: 98
- **Activity level**: ACTIVE
- **Contact**: Email not found — affiliated with Unknown

## 5. Sources & References
- BigQuery database for disease information and associated targets.
- OpenAlex Author Profile: https://openalex.org/A5036921698
- OpenAlex Author Profile: https://openalex.org/A5073254862
- OpenAlex Author Profile: https://openalex.org/A5002887053
- OpenAlex Author Profile: https://openalex.org/A5009387550
- OpenAlex Author Profile: https://openalex.org/A5078405859
- Vertex AI Search grounding for general IPF information.

## 6. Raw Artifacts
- gs://benchspark-artifacts-lazy-coders-1771991986/runs/session-1772206554314-662cww/S1.json
- gs://benchspark-artifacts-lazy-coders-1771991986/runs/session-1772206554314-662cww/S2.json
- gs://benchspark-artifacts-lazy-coders-1771991986/runs/session-1772206554314-662cww/S4.json
- gs://benchspark-artifacts-lazy-coders-1771991986/runs/session-1772206554314-662cww/S5.json

## 7. Next-Step Suggestions
1.  **Refine Search Strategy for IPF-Specific Treatments**: The current search identified researchers broadly in lung diseases or transplantation, but not specifically on IPF treatments. Future searches should include more specific keywords like "IPF antifibrotic therapies", "novel IPF drugs", "clinical trials IPF treatment" to narrow down to researchers focused on therapeutic interventions for IPF.
2.  **Investigate Publications of Identified Researchers for "Hidden" Relevance**: Although the initial analysis indicated a shift in focus for some researchers, a deeper dive into their non-primary publications or review articles might reveal tangential contributions or expert opinions relevant to IPF treatment. This could involve manually reviewing abstracts or full texts of their works.
3.  **Broaden Scope to Institutions/Clinical Trials**: Instead of solely focusing on individual researchers, the next step could involve searching for institutions or clinical trials actively engaged in IPF treatment research in the last three years. This might uncover researchers who are part of larger teams or clinical networks that are more directly involved in therapeutic development.